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ABSTRACT
Background & objectives: Homeopathy is considered as an emerging area of alternative medicine which could
be established for the global health care. One of the greatest objections to this science lies in its inability to
explain the mechanism of action of the micro doses based on scientific experiments and proofs. The present
study has been undertaken to screen in vivo antimalarial activity of Malaria Co Nosode 30 and Nosode 200
against Plasmodium berghei infection in BALB/c mice.
Methods: Peter’s 4-day test was used to evaluate the in vivo schizontocidal effect of Nosode 30 and Nosode 200.
One month follow-up study was done to calculate the mean survival time of mice in each group. Biochemical
analysis was carried out to assess the liver and kidney function tests using diagnostic kits.
Results: Nosode 30 and 200 exhibited 87.02 and 37.97% chemosuppression on Day 7 and mean survival time
(MST) of 18.5 ± 2.16 and 16.5 ± 1.37 days respectively, which were extremely statistically significant when
compared to MST of infected control (8.55 ± 0.83 days).  The safety of Nosode 30 was also confirmed by the
comparable levels of ALP, SGOT, SGPT activities, concentration of bilirubin, urea and creatinine to CQ treated
group.
Conclusion: Nosode 30 possesses considerable in vivo antiplasmodial activity against P. berghei infection as
compared to  Nosode 200 as evident from the chemosuppression obtained using Peter’s 4-day test. Further,
studies on the drug can be carried out to establish its antimalarial potential in monotherapy or in combination
with other homeopathic drug formulations.
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INTRODUCTION
Antimalarial chemotherapy for decades is cheap, safe
and practicable for outpatient use but resistance to cheap
efficient antimalarial drugs cause a major problem. Ho-
meopathy is a system of curing diseases with very minute
doses of medicine. In homeopathy, crude drug substance
is diluted and triturated or succussed to increase its po-
tency by virtue of which, only the medicinal power of the
substance is retained and drug related side-effects are elimi-
nated. Hahnemann, father of homeopathy believed that
‘Vital force’ of a substance was somehow released by the
process of ‘succussion/potentization’ to the ‘vehicle’ which
now behaved as the medicine1.
Homeopaths also use treatments called Nosodes made
from diseased or pathological products such as faecal,
urinary or respiratory discharges, blood and tissue. Ma-
laria officinalis/Malaria Co Nosode is not a discharge
but is called vegetable nosode as it is swamp mire that has
been potentised. It was found that the Malaria Nosode is
made out of the rotting vegetation from marsh areas where
the mosquito breeds. The ‘African’ homeopaths recom-
mended Malaria Co Nosode 30 on a weekly basis for visi-
tors, starting a week before arrival for recurring parasite
which lingers in liver for months. It is one of the most
frequently used antimalarials in homeopathy, but there is
no provings record. A routine of prophylaxis was given in
the form of Abha light complex 30C remedies that con-
tain 5 ingredients, one of them being Malaria Nosode, sold
by Ainsworth Pharmacy, UK which contains four malarial
(Plasmodium falciparum, P. vivax, P. ovale and P.
malariae) and Anopheles mosquitoes. The malaria com-
plex was found very effective in preventing malaria in Kenya.
All recommended prophylaxis for visitors2. Homeopathy is
the second largest system in the world, widely used and
economical but lacks some evidence based research and data
in order to prove its efficacy to the scientific community.
China another homeopathic antimalarial is also reported to
have schizonticidal activity against lethal rodent malaria
parasite. The drug enhanced the mean survival time of the
mice and also found safe on the morphology of red blood
cells of the host as observed in SEM studies3. Present re-
search work is an effort to provide most authentic informa-
tion about antimalarial Nosode 30 and Nosode 200 to their
in vivo antimalarial activity against P. berghei (NK-65)
infection in BALB/c mice. 73 Bagai et al: Homeopathy against malaria
MATERIAL & METHODS
Mouse and parasite strain
White swiss mice Mus musculus of BALB/c strain
(weighing 22–26 g and 4-6 wk old) of either sex, obtained
from the Central Animal House, Panjab University,
Chandigarh were used as experimental model. They were
maintained on a standard pellet diet and water ad libitum.
P. berghei (NK- 65) was maintained by i.p. inoculation
of 1×106 parasitized RBCs from infected to naïve mice.
Parasitaemia was checked by preparing Giemsa stained
thin blood smears through tail vein incision of infected
mice4. The treatment of mice was according to the guide-
lines of committee for the purpose of control and supervi-
sion on experiments on animals (Reg. No. 45/1999/
CPCSEA), Panjab University, Chandigarh.
Drugs used
The 30 and 200 potency of homeopathic Nosode (Ma-
laria Co Nosode [Nd]) manufactured by M/s. S.B.L. In-
dia were used in the present study. These drugs were di-
luted with distilled water in the ratio 1:2 (v/v) before
administration. Chloroquine (LARIAGO Chloroquine
phosphate suspension containing 50 mg base) manufac-
tured in India, was given to positive control and chloro-
quine 20 mg/kg was prepared in distilled water.
Evaluation of antiplasmodial activity of Nosode (Nd 30
and Nd 200)
Six groups having 6 mice each (same sex and age)
were used for the present study and the groups were des-
ignated as G1 to G6 (Table 1). All groups except G-1
(normal control) were injected with 1×106 P. berghei para-
sitized RBCs i.p. on D0 and treated for 4 consecutive days
(D0–D3). G1and G2 mice were administered 0.2 ml of
distilled water and were kept as normal control and in-
fected control group respectively. Homeopathic drugs Nd
30 and Nd 200 and CQ (20 mg/kg) as positive control
were evaluated for their schizontocidal effect using Peter
4-day test.
Blood smears were prepared from tail vein incision
on D5 and D7 followed by weekly examination of blood
smears up to 1 month follow up period (i.e. Day 14, 21
and 28). Blood films were stained with Giemsa and exam-
ined microscopically. The degree of infection was recorded
as the percentage parasitaemia. Average chemosuppression
for each group and mortality of mice (evaluated as mean
survival time period (MST) in each group were determined
arithmetically.
Biochemical analysis
The therapeutic efficacy of antimalarial drugs was
checked by biochemical analysis (liver and kidney func-
tion tests) on Day 7 for G1 and G2 mice and on Day 10
and Day 28 for G3 to G6 mice. The biochemical kits used
for assays were manufactured by M/s. Reckon Diagnos-
tic Pvt. Ltd. and M/s. Span Diagnostic Ltd.  Blood was
collected by tail vein incision of mice from each group.
Unhaemolyzed serum was collected and diluted with 0.9%
saline.
Statistical analysis
Data have been presented as mean and standard de-
viation (SD). Statistical evaluation of differences between
the experimental groups was determined by the Student’s
t-test with the level of significance of p <0.05.
RESULTS
In vivo antiplasmodial efficacy of Nd 30 and Nd 200
All the mice of infected control (G2) died by Day 9
(Fig. 1a). Mice of G3 negative control also exhibited nor-
mal course of infection with 31.62±3.37% infection on
Day 7 after which all the mice died within Day 10 (Fig.
1b) showing that vehicle (nascent alcohol) itself has no
effect in clearing the rodent malaria parasite (Table 1).
Table 1. Parasitaemia and chemosuppression along with mean survival time period of various experimental groups
Groups Dosage (0.2 ml OD/Day/mouse) Parasitaemia Chemosuppression Mean survival
(n=6) i.p. infection of 1×10
6 infected RBC’s  (%) on Day 7  (Day 7) time (days)
G1 Distilled water (infected D0) at –– –
G2 Distilled water (infected D0) 30.44 ± 3.40 – 8.55 ± 0.83
G3 Nascent alcohol (1:2) 31.62 ± 3.37 – 8.83 ± 1.03
G4 CQ (20 mg/kg), infected on D0 0.6 ± 0.3* 96.7 28 ± 0
G5 Nd 30 (D0–D3), infected on D0 3.95 ± 0.9* 87.02 18.5 ± 2.16
G6 Nd 200 (D0-D3), infected on D0 18.88 ± 1.31* 37.97 16.5 ± 1.37
Note: All the groups except G1 were injected with 1 × 106 infected RBC on Day 0; Data are given as mean ± SD. p-value in comparison to
infected control (G2 group) is shown as *extremely statistically significant (p <0.0005). J Vector Borne Dis 49, June 2012 74
In group G4 (CQ 20 mg/kg), the parasitaemia was
0.34±0.1% on Day 5 which continuously increased up to
2.3±1% by Day 14 after which the parasitaemia declined
to 0.24 ± 0.2% on Day 28 (Fig. 1c). CQ exhibited 96.7%
chemosuppression and MST of 28 days which was maxi-
mum among the treated groups.
The infection observed in G5 group (Nd 30) was
1.02±0.13% on Day 5 which increased to 3.95±0.9%
(p <0.0005) by Day 7 with 87.02% chemosuppression.
The parasitaemia further increased to 14.69±0.73% and
only one mouse survived till Day 21 (Fig. 2a) showing
MST of 18.5±2.16 days. In G6 group (Nd 200),
parasitaemia on Day 5 was 1.47±0.43% which increased
to 18.18±1.31% by Day 7, followed by decrease in
parasitaemia to 16.09±2.41% on Day 14 (Fig. 2b). In this
group also, only one mouse survived till Day 21. Average
chemosuppression was 37.97% and mean survival time
was 16.5±1.37 (p <0.0005) days which was lowest among
the treated groups but significantly higher than the MST
of infected control.
Biochemical assays
The alkaline phosphatase (ALP) activity of enzyme
in sera of normal mice was recorded to be 7.33±0.98 KA.
It increased significantly in the infected mice 35.27±4.69
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Fig. 1: Graph showing course of infection in BALB/c mice (G2
group) infected with 1×106 P .berghei parasitized red blood
cells : (a) treated with nascent alcohol (G3 group); (b)
chloroquine (G4 group);  and (c) Data expressed as
Mean±SD of six mice. Parasitaemia (%)  of G2 group =
30.44±3.40, G3 group = 31.62 ± 3.37  on Day 7; and  G4 =
0.6±0.3, 2.3±1 and 0.24±0.2 on Days 7,  14 and  28
respectively.
Fig. 2: Graph showing course of infection in BALB/c mice treated
with Nosode 30 (G5 group): (a) Nosode 200 (G6 group);
and (b) Data expressed as Mean±SD of six mice.
Parasitaemia (%) of G5 group = 3.95±0.9, 14.69; G6 group =
18.18±1.31, 16.09±2.41 on Days 7 and 14,  respectively.
(a)
(b)
(a)
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KA which was five times the normal value. Similar activ-
ity was found in G3 group (34.34±5.41 KA). A signifi-
cant decrease in ALP activity was observed in G4 group
by the Day 28 (6.6±2.5 KA) as compared to Day 10
(12.3±1.3 KA). In G6 group, ALP activity was maximum,
i.e. 28.84±3.21 KA followed by G5 group (12±4.45 KA)
on Day 10. Serum bilirubin level was also found to be
increased in G2 group (2.31±0.31mg/dl) and G3 group
(1.87±0.12 mg/dl) as compared to G1 group (0.65±0.27
mg/dl). The concentration of bilirubin was maximum in
G6 group (2.29±0.23 mg/dl) followed by G4 and G5
groups. In G4 group, the bilirubin concentration decreased
from 1.78±0.2  mg/dl on Day 10 to 1.5±0.11 mg/dl on
Day 28 (Table 2).
Serum glutamate oxaloacetate transaminase (SGOT)
activity was found to be 13.68±0.55 U/l in G1 group while
in G2 and G3 groups it was increased more than six times,
i.e. 76.46 ± 0.82 U/l and 80±12.24 U/l respectively. In
G4 group, SGOT activity was 44±5.02 U/l on Day 10
and 23±4.3 U/l on Day 28. SGOT activity was observed
maximum in G6 group (56.46±9.54 U/l), followed by G5
group (47.05±4.06 U/l). Serum glutamate pyruvate tran-
saminase (SGPT) activity was also found five times more
in G2 (133.19±3.09 U/l) and G3 (131.05±6.12 U/l) than
G1 (29.0±0.20 U/l).  SGPT activity was found maximum
in G6 group (128.63±1.2 U/l), followed by G5 group
(87.23±8.82 U/l), G4 group (60±3.8 U/l on Day 10 and
58±6.2 U/l on Day 28).
In G1 group the level of serum urea was determined
to be 32.0±1.05 mg/dl which increased two fold to 62.6±
2.25 mg/dl in G2 group than normal value. In positive
control, there was decrease in concentration of urea on
Day 10 from 59.3±3.3 mg/dl to 52±6.2 mg/dl on Day 28.
Serum urea was found maximum in G6 group (106.66±
9.81 mg/dl) followed by G5 group (73.33±5.22 mg/dl).
Increased creatinine concentration is an indicative of re-
nal diseases which was evident in G2 group (4.57±0.18
mg/dl) and G3 group (4.49 ± 0.08 mg/dl) as compared to
normal mice (1.04 ± 0.18 mg/dl). Concentration of creati-
nine in G4 group was 5.5 ± 1.02 mg/dl on Day 10 which
decreased to 4.1 ± 0.3 mg/dl on Day 28. Its concentration
was 2.34 ± 0.16 mg/dl in G6 group and 2.04 ± 0.30 mg/dl
in G5 group.
DISCUSSION
The antimalarial chemotherapy is the keystone of
malaria control efforts. But the major problem to the use
of antimalarial drugs is resistance developed by the para-
site5. Homeopathy offers more affordable and safer ap-
proach to disease management. In the present study,
antiplasmodial efficacy of homeopathic drugs Nd 30 and
Nd 200 has been evaluated in vivo.
Lethality of P. berghei to mice has been reported by
many workers6. P. berghei preferentially invades reticu-
locytes7–9 and its infection is associated with mortality rates
which are confirmed in the present study too. When ve-
hicle (nascent alcohol) was administered to BALB/c mice
the parasitaemia on Day 7 was comparable to infected
control group, indicating that vehicle does not provide any
protection and have no placebo effect. The homeopathic
medicines have been shown effective than placebo con-
trols in 60 (43.5%) findings of 138 randomized controlled
trials till 2008. In drug treated groups, the chemo-
suppression of Nd 30 was 87.02% on Day 7 which was
higher than Nd 200 treated group. The mean survival time
period was also more in Nd 30 (18.5±2.16 days).
 This observation is in accordance with the earlier stud-
ies where 30 potency of homeopathic drugs China, Cheli-
donium and Artemisia vulgaris were found to be very
effective against rodent malaria parasite exhibiting maxi-
mum chemosuppression and enhancement of mean sur-
Table 2. Alterations in ALP activity, bilirubin concentration, SGOT activity, SGPT activity, concentration of urea and creatinine in
various experimental groups on Day 7 and Day 10
Group ALP Bilirubin SGOT SGPT Urea Creatinine (mg/dl)
(KA units) (mg/dl) activity (U/l) activity (U/l) (KA units)
G1 (D 7) 7.33 ± 0.98 0.65 ± 0.27 13.68 ± 0.55 29 ± 0.2 32.0 ± 1.05 1.04 ± 0.18
G2 (D 7) 35.27 ± 4.69 2.31 ± 0.31 76.46 ± 0.82 133.19 ± 3.09 62.6 ± 2.25 4.57 ± 0.18
G3 (D 7) 34.34 ± 5.41 1.87 ± 0.12 80 ± 12.24 131.05 ± 6.12 74.05 ± 10.47 4.49 ± 0.08
G4 (D 10) 12.3 ± 1.3*** 1.78 ± 0.2** 44 ± 5.02*** 60 ± 3.8*** 59.3 ± 3.3# 5.5 ± 1.02#
     (D 28) 6.6 ± 2.5*** 1.5± 0.11*** 23 ± 4.3*** 58 ± 6.2*** 52 ± 6.2** 4.1 ± 0.3*
G5 (D 10) 12 ± 4.45*** 1.10 ± 0.21*** 47.05 ± 4.06*** 87.23 ± 8.82*** 73.33 ± 5.22*** 2.04 ± 0.30***
G6 (D 10) 28.84 ± 3.21* 2.29 ± 0.23# 56.46 ± 9.54*** 128.63 ± 1.2* 106.66 ± 9.81*** 2.34 ± 0.16***
Note: Data are given as mean±SD; p-value in comparison to infected control (G2) is shown as ***extremely statistically significant
(p<0.0005), **very statistically significant (p <0.005), *statistically significant (p <0.05), #not statistically significant (p >0.05) . J Vector Borne Dis 49, June 2012 76
vival time of mice10–13. According to the Hahnemann, any
disease may remain unaffected by the lowest potency,
whereas, higher potency  probably is too powerful which
may cause adverse effect, so use of correctly selected
medium potency may prove more effective14. It has been
reported that Cinchona officinalis (China) can be taken
as prophylactic drug in a 30 C dose weekly prior to enter-
ing a malarial zone15. All these findings establish that the
30 potency of homeopathic drug formulations is most
effective against the malaria parasite as compared to lower/
higher  potencies which is observed in the present study
too.
 In positive control (CQ 20 mg/kg) on Day 7, chemo-
suppression was 96.7% and mean survival time was 28
days which was again in accordance with the earlier stud-
ies in which mice inoculated with 1×105, 1×106, 1×107
pRBC and then treated with chloroquine (20 mg/kg)
showed a marked effect with the mean survival more than
28 days16 .
The functioning of liver and kidney was also checked
by measuring the levels of serum alkaline phosphatase
activity, concentration of bilirubin, SGOT activity, SGPT
activity, urea and creatinine concentration. The increased
serum ALP activity among patients indicate that the liver
stage of malaria infection accompanied by perturbation
of the host hepatocytes membrane leading to leakage of
this enzyme out of liver cells17. In the present study also,
the activity of serum alkaline phosphatase in G2 (35.27±
4.69 KA) and G3 (34.34±5.41 KA) groups was increased
twice in comparison to normal mice (7.33±0.98 KA). In
positive control, it was 12.3±1.3 KA on Day 10 which
decreased to 6.6±2.5 KA on Day 28. Studies have shown
that chloroquine affects a wide range of biochemical pro-
cesses including inhibition of key metabolic enzymes such
as alcohol dehydrogenase, succinate dehydrogenase and
glucose-6-phosphate dehydrogenase18,19. ALP activity was
maximum in G6 (28.84±3.21 KA) group, followed by G5
group (12±4.45 KA) almost comparable amount of ALP
activity to normal mice prompting the safety of homeo-
pathic formulation for liver of host.
Serum bilirubin concentration (>3 mg/dl) is a com-
mon feature attributed in part to liver damage and
haemolysis of parasitized and non-parasitized cells20. In
infected control, bilirubin concentration was observed to
rise four times as compared to normal. While in chloro-
quine treated group bilirubin concentration was 1.78±0.2
mg/dl. The serum bilirubin levels were observed to in-
crease in all treated groups indicating jaundice like symp-
toms.
The ratio of AST to ALT is useful in differentiating
between causes of liver damage21,22. SGOT activity in-
creased six times in infected control and vehicle treated
group than the normal control. In G4 group, SGOT activ-
ity was decreased by Day 28 which was comparable to
normal value. The results of the present study revealed a
significant increase of serum transaminases. The eleva-
tion during acute infection results in necrosis of hepatic
cells. These enzymes are released into the circulation with
consequent rise in the serum levels23–25. SGPT activity
was observed to rise in all treated groups. In chloroquine
treated (G4) group also, considerable increase in SGPT
activity was recorded.
Serum urea and creatinine concentration are used for
the assessment of renal sufficiency26. There was signifi-
cant increase in serum urea and creatinine in infected con-
trol as compared to normal. Higher levels of serum urea
and creatinine are indications of deficiency in renal func-
tion27–29. All the treated groups recorded increase in se-
rum urea levels. Chloroquine administration is also re-
ported to impair kidney function, resulting inappropriate
Na+ and Cl– retention30. In the present study also, the crea-
tinine levels were also considerably elevated in CQ treated
group indicating impairment of kidney function. In treated
groups, the increase in creatinine concentration was less
as compared to P. berghei infected mice.
CONCLUSION
These findings suggest that chemosuppression ob-
served in Nd 30 treated group is considerable. Further
studies are needed to establish Malaria Co Nosode 30 (Nd
30) as potent antimalarial in monotherapy or in combina-
tion therapy with other homeopathic formulations.
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